Fredun Pharmaceuticals Ltd Financials

Fredun Pharmaceuticals Ltd Financial Statement

Fredun Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Sep 2024	Jun 2024	Mar 2024
Revenue	107.35	78.81	118.03
Operating Expense	93.40	68.33	106.87
Net Profit	4.27	4.13	5.06
Net Profit Margin	3.98	5.24	4.29
Earning Per Share	9.05	8.79	10.77
EBIDTA	13.94	10.48	11.17
Effective Tax Rate	23.66	13.26	6.98

Particulars	Sep 2024
Revenue	107.35
Operating Expense	93.40
Net Profit	4.27
Net Profit Margin	3.98
Earning Per Share	9.05
EBIDTA	13.94
Effective Tax Rate	23.66

Fredun Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	348.16	274.68	224.46
Operating Expenses Annual	310.17	246.90	210.66
Operating Profit Annual	38.90	29.60	15.43
Interest Annual	13.65	9.28	4.67
Depreciation	3.80	2.81	2.16
Net Profit Annual	15.62	10.81	6.34
Tax Annual	5.83	6.70	2.26

Particulars	Mar 2024
Total Revenue Annual	348.16
Operating Expenses Annual	310.17
Operating Profit Annual	38.90
Interest Annual	13.65
Depreciation	3.80
Net Profit Annual	15.62
Tax Annual	5.83

Fredun Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	3.44	2.07	1.13
Cash Flow from Operations	-0.44	-14.41	-2.38
Cash Flow from Investing	-7.64	-9.40	-4.14
Cash Flow from Financing	5.99	25.18	7.47
Cash Flow at the End	1.35	3.44	2.07

Particulars	Mar 2024
Cash Flow at the Beginning	3.44
Cash Flow from Operations	-0.44
Cash Flow from Investing	-7.64
Cash Flow from Financing	5.99
Cash Flow at the End	1.35

Fredun Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	11.17	10.78	6.91
PBIT Margin (%)	10.08	9.75	5.94
PBT Margin (%)	9.34	8.70	4.69
Net PROFIT Margin (%)	4.49	3.94	2.82
Return On Networth / Equity (%)	14.34	13.15	11.41
Return On Networth /Employed (%)	16.95	17.43	12.90
Return On Assets (%)	7.54	7.04	6.13
Total Debt / Equity (X)	0.88	0.85	0.83
Asset Turnover Ratio (%)	1.68	1.79	2.17

Particulars	Mar 2024
PBDIT Margin (%)	11.17
PBIT Margin (%)	10.08
PBT Margin (%)	9.34
Net PROFIT Margin (%)	4.49
Return On Networth / Equity (%)	14.34
Return On Networth /Employed (%)	16.95
Return On Assets (%)	7.54
Total Debt / Equity (X)	0.88
Asset Turnover Ratio (%)	1.68

Fredun Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	46.57	38.93	32.34
Total Current Assets Annual	257.20	216.21	152.65
Non Current Assets Annual	50.40	41.07	34.34
Total Shareholders Funds Annual	121.47	96.38	68.06
Total Assets Annual	307.60	257.28	186.99

Particulars	Mar 2024
Fixed Assets Annual	46.57
Total Current Assets Annual	257.20
Non Current Assets Annual	50.40
Total Shareholders Funds Annual	121.47
Total Assets Annual	307.60

Fredun Pharmaceuticals Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 26, 2024, Fredun Pharmaceuticals Ltd has a market capitalization of 337.07 Cr. Value Research classifies it as a Small-Cap company.

No, Fredun Pharmaceuticals Ltd is not debt-free with a debt-to-equity ratio of 0.87.

In FY 2023 , Fredun Pharmaceuticals Ltd recorded a total revenue of approximately 346.58 Cr marking a significant milestone in the company's financial performance.

Fredun Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.2% annually, respectively..

Fredun Pharmaceuticals Ltd's current PE ratio is 21.58.

Fredun Pharmaceuticals Ltd's ROCE averaged 13.7% from the FY ending March 2022 to 2024, with a median of 14.6%. It peaked at 15.5% in March 2024, reflecting strong capital efficiency over the period..

Fredun Pharmaceuticals Ltd's latest EBIT is Rs. 35.10 Cr, surpassing the average EBIT of Rs. 25.05 Cr over the 5 years..